

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**POST-EFFECTIVE AMENDMENT NO. 1 TO**

- Form S-8 Registration Statement No. 33-5111
- Form S-8 Registration Statement No. 2-86618
- Form S-8 Registration Statement No. 2-91724
- Form S-8 Registration Statement No. 33-24013
- Form S-8 Registration Statement No. 33-29791
- Form S-8 Registration Statement No. 333-144678
- Form S-8 Registration Statement No. 333-92424
- Form S-8 Registration Statement No. 333-132932
- Form S-8 Registration Statement No. 333-118254
- Form S-8 Registration Statement No. 333-74585
- Form S-8 Registration Statement No. 333-141304

**UNDER  
THE SECURITIES ACT OF 1933**

**AMGEN INC.**

*(Exact name of registrant as specified in its charter)*

**Delaware**  
*(State of Incorporation)*

**95-3540776**  
*(I.R.S. Employer Identification No.)*

**One Amgen Center Drive  
Thousand Oaks, California 91320-1799  
(805) 447-1000**

*(Address of principal executive offices, including zip code)*

- 1984 Stock Option Plan**
- 1981 Incentive Stock Option Plan**
- Nonqualified Stock Option Plan of Amgen Inc.**
- Amended and Restated 1988 Stock Option Plan of Amgen Inc.**
- Amended and Restated 1987 Directors' Stock Option Plan**
- Amgen Inc. Assumed Ilypsa, Inc. Stock Plan (f/k/a the Ilypsa Inc. 2003 Stock Plan)**
- Immunex Corporation Stock Option Plan for Nonemployee Directors**
- Amgen Inc. Amended and Restated 1999 Employee Stock Purchase Plan (f/k/a the Immunex Corporation 1999 Employee Stock Purchase Plan)**
- Amgen Inc. Profit Sharing 401(k) Plan and Trust (f/k/a the Immunex Corporation Profit Sharing 401(k) Plan and Trust)**
- Abgenix, Inc. 1998 Director Option Plan, as amended and restated**
- Tularik Inc. 1991 Stock Plan, as amended**
- Tularik Inc. Amended and Restated 1997 Non-Employee Directors' Stock Option Plan, as amended**
- Amgen Salary Savings Plan (f/k/a Tularik Salary Savings Plan)**
- Perlman Nonstatutory Stock Option Agreement**
- Amgen Limited Sharesave Plan**
- Amgen Technology Ireland Irish Tax Approved Share Plan**

*(Full title of the plan)*

**David J. Scott, Esq.**  
**Senior Vice President, General Counsel  
and Secretary**  
**One Amgen Center Drive  
Thousand Oaks, California 91320-1799  
(805) 447-1000**

*(Name, address, including zip code, and telephone number, including area code, of agent for service)*

**Copy to:**  
**Charles K. Ruck**  
**Latham & Watkins LLP**  
**650 Town Center Drive, Suite 2000**  
**Costa Mesa, California 92626**  
**(714) 540-1235**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act (Check one):

- |                         |                                     |                           |                          |
|-------------------------|-------------------------------------|---------------------------|--------------------------|
| Large Accelerated filer | <input checked="" type="checkbox"/> | Accelerated filer         | <input type="checkbox"/> |
| Non-Accelerated filer   | <input type="checkbox"/>            | Smaller reporting company | <input type="checkbox"/> |

(Do not check if a smaller reporting company)

**EXPLANATORY NOTE / DEREGISTRATION OF UNSOLD SECURITIES**

Amgen Inc. (the “Company”) previously registered shares of the Company’s common stock, \$0.0001 par value per share, under the following registration statements (the “Registration Statements”) concerning shares issuable under certain employee benefit and equity plans and agreements. The Company is filing these post-effective amendments to the Registration Statements (“Post-Effective Amendments”) in order to deregister any securities registered and unsold under the Registration Statements and to terminate the Registration Statements. The approximate number of unsold shares is set forth below with respect to each Registration Statement. The shares are being removed from registration and the Registration Statements are being terminated because the plans referenced below have now expired or been terminated and all shares that were issuable under the plans have been issued.

Registration No.	Date Filed With the SEC	Name of Equity Plan or Agreement	Number of Shares Originally Registered <sup>1</sup>	Approximate Number of Shares Deregistered <sup>2</sup>
2-91724	6/15/84	1984 Stock Option Plan	3,000,000	0
33-5111	4/23/86		7,200,000	2,502,928
2-86618	9/20/83	1981 Incentive Stock Option Plan and Nonqualified Stock Option Plan of Amgen Inc.	47,987,328	7,815,552
33-24013	8/26/88	Amended and Restated 1988 Stock Option Plan of Amgen Inc.	36,000,000	249,224
33-29791	7/6/89	Amended and Restated 1987 Directors’ Stock Option Plan	4,800,000	0
33-42501	8/28/91		2,400,000	2,112,052
333-144678	7/18/2007	Amgen Inc. Assumed Ilypsa, Inc. Stock Plan (f/k/a the Ilypsa Inc. 2003 Stock Plan)	21,992	3,494
333-92424	7/16/2002	Immunex Corporation Stock Option Plan for Nonemployee Directors	347,880	15,600
		Amgen Inc. Amended and Restated 1999 Employee Stock Purchase Plan (f/k/a the Immunex Corporation 1999 Employee Stock Purchase Plan)	1,298,005	1,251,841
		Amgen Inc. Profit Sharing 401(k) Plan and Trust (f/k/a the Immunex Corporation Profit Sharing 401(k) Plan and Trust)	649,455	432,235
333-132932	4/3/2006	Abgenix, Inc. 1998 Director Option Plan, as amended and restated	89,900	0
333-118254	8/16/2004	Tularik Inc. 1991 Stock Plan, as amended	38,710	4,059
		Tularik Inc. Amended and Restated 1997 Non-Employee Directors’ Stock Option Plan, as amended	90,200	39,689
		Amgen Salary Savings Plan (f/k/a Tularik Salary Savings Plan)	28,664	28,304
		Perlman Nonstatutory Stock Option Agreement	9,020	0
333-74585	3/17/1999	Amgen Limited Sharesave Plan	400,000	372,839
333-141304	3/15/2007	Amgen Technology Ireland Irish Tax Approved Share Plan	600,000	592,168

<sup>1</sup> The number of shares originally registered have been adjusted as appropriate to reflect the following stock splits effected by the Company: 2 for 1 stock split on August 10, 1990; 3 for 1 stock split on September 10, 1991; 2 for 1 stock split on August 15, 1995; 2 for 1 stock split on February 26, 1999; and 2 for 1 stock split on November 19, 1999.

<sup>2</sup> A “0” in this column indicates that all shares originally registered under the registration statement were issued.

**SIGNATURES**

In accordance with the requirements of the Securities Act of 1933, as amended, the registrant, Amgen Inc., certifies that it has reasonable grounds to believe that it meets all of the requirements for filing these Post-Effective Amendments and has duly caused and authorized the officers whose signatures appear below to sign these Post-Effective Amendments on its behalf by the undersigned, in the City of Thousand Oaks, State of California, on November 6, 2009.

AMGEN INC.

By: /s/ David J. Scott

David J. Scott

Senior Vice President, General Counsel and Secretary

## POWER OF ATTORNEY

Each person whose signature appears below hereby authorizes and appoints Kevin W. Sharer and Robert A. Bradway and David J. Scott as attorneys-in-fact and agents, each acting alone, with full powers of substitution to sign on his behalf, individually and in the capacities stated below, and to file any and all amendments (including these Post-Effective Amendments filed herewith) to the Registration Statements listed herein above, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting to those attorneys-in-fact and agents full power and authority to perform any other act on behalf of the undersigned required to be done.

Pursuant to the requirements of the Securities Act of 1933, these Post-Effective Amendments have been signed by the following persons in the capacities and on the dates indicated.

<u>Signature</u>	<u>Title</u>	<u>Date</u>
<u>/s/ Kevin W. Sharer</u> Kevin W. Sharer	Chairman of the Board, Chief Executive Officer and President, and Director (Principal Executive Officer)	November 6, 2009
<u>/s/ Robert A. Bradway</u> Robert A. Bradway	Executive Vice President and Chief Financial Officer (Principal Financial Officer)	November 6, 2009
<u>/s/ Michael A. Kelly</u> Michael A. Kelly	Vice President, Finance and Chief Accounting Officer (Principal Accounting Officer)	November 6, 2009
<u>/s/ David Baltimore</u> David Baltimore	Director	November 6, 2009
<u>/s/ Frank J. Biondi, Jr.</u> Frank J. Biondi, Jr.	Director	November 6, 2009
<u>/s/ François de Carbonnel</u> François de Carbonnel	Director	November 6, 2009
<u>/s/ Jerry D. Choate</u> Jerry D. Choate	Director	November 6, 2009
<u>/s/ Vance D. Coffman</u> Vance D. Coffman	Director	November 6, 2009
<u>/s/ Frederick W. Gluck</u> Frederick W. Gluck	Director	November 6, 2009

/s/ Rebecca M. Henderson

Director

November 6, 2009

Rebecca M. Henderson

/s/ Frank C. Herringer

Director

November 6, 2009

Frank C. Herringer

/s/ Gilbert S. Omenn

Director

November 6, 2009

Gilbert S. Omenn

/s/ Judith C. Pelham

Director

November 6, 2009

Judith C. Pelham

/s/ J. Paul Reason

Director

November 6, 2009

J. Paul Reason

/s/ Leonard D. Schaeffer

Director

November 6, 2009

Leonard D. Schaeffer

**EXHIBIT INDEX**

<u>Exhibit Number</u>	<u>Description</u>
24.1	Power of Attorney (included on signature page)